A New Standard of Care for Improving Patient Outcomes
PT/INR patient self-testing is approved by Medicare (CMS) and most private insurers for these conditions requiring warfarin oral anticoagulation:
Clinical benefits of self-testing:
-
Helps maintain patients in therapeutic range, which may reduce the potential for drug-related complications and emergency room visits
-
Reducing the potential for drug-related complications and ER visits may have a positive impact on costs associated with anti-coagulation
-
Provides timely alert to clinicians when patients are out of range
Provides greater support for anticoagulation therapy compliance:
-
Recent study in the New England Journal of Medicine cites warfarin as the leading cause of emergency room admissions among the elderly.
-
By contacting patients with reminders to test if weekly results are not received, Philips Patient Self-Testing service offers clinicians and their patients a high degree of support for anticoagulation therapy.
When testing patients with mechanical heart valves, Medicare advises: “In order to achieve time in therapeutic range of greater than 90%, a patient most likely needs to test once a week.” 1
Learn about recently published research on patient self-testing
1 Decision Memo for Prothrombin Time (INR) Monitor for Home Anticoagulation Management. (#CAG-00087N) National Coverage Analysis. Baltimore, MD: Centers for Medicare and Medicaid Services; September 18, 2001
● Helps maintain patients in therapeutic range, which may reduce the potential for drug-related complications and emergency room visits
|
